Drug Interactions between Dura-Ron and trichophyton skin test
This report displays the potential drug interactions for the following 2 drugs:
- Dura-Ron (carbinoxamine/pseudoephedrine)
- trichophyton skin test
Interactions between your drugs
carbinoxamine trichophyton skin test
Applies to: Dura-Ron (carbinoxamine / pseudoephedrine) and trichophyton skin test
ADJUST DOSING INTERVAL: Systemic antihistamines may diminish the response to the trichophyton diagnostic skin test and lead to falsely insignificant or false-negative results. The proposed mechanism is inhibition of histamine release in the skin leading to suppression of the wheal and flare response. This interaction has been documented in numerous studies examining allergenic extracts and different antihistamines, but clinical data with the trichophyton diagnostic skin test are not readily available.
MANAGEMENT: The labeling for the trichophyton skin test recommends avoiding use of antihistamines for at least 24 hours prior to skin testing, though longer may be required depending on the specific antihistamine in question. Consultation with the labeling of the individual antihistamine as well as any relevant local and/or national guideline(s) is advisable.
References (3)
- "Multum Information Services, Inc. Expert Review Panel"
- (2007) "Product Information. Trichophyton Extracts (trichophyton skin test)." Allermed Laboratories Inc
- Bernstein L, Li JT, Bernstein DI, et al. (2008) "Allergy diagnostic testing: an updated practice parameter." Ann Allergy Asthma Immunol, 100, S1-148
Drug and food interactions
carbinoxamine food
Applies to: Dura-Ron (carbinoxamine / pseudoephedrine)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
pseudoephedrine food
Applies to: Dura-Ron (carbinoxamine / pseudoephedrine)
MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.
MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.
References (7)
- Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
- Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
- (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
- (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
- (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
- (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
- (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.